CLEVELAND and DALLAS, November 5, 2025 | Align Capital Partners’ (“ACP”) drugs and alcohol testing solutions provider Premier Biotech (“Premier” or the “Company”) has acquired National Test Systems (“NTS”), a leading provider of rapid point-of-care diagnostic drug screening supplies and services throughout the United States.
NTS serves over 1,500 facilities throughout the United States, primarily in Government and Behavioral Health end markets through a consultative, knowledge-first approach. The addition of NTS enhances Premier’s customer base and strengthens the Company’s leadership within the Government and Behavioral Health channel. NTS CEO, Andrew Panico, will remain involved with the Company to support continued growth and a successful transition.
“We are excited about the partnership opportunity to bring Premier’s full suite of products and services to our growing customer base. Specifically, Premier’s offering in oral fluid testing with its OralTox® device and complete laboratory solutions provides new ways for us to support our customers,” said Panico.
“The acquisition marks a pivotal step in our growth journey and bolsters our leadership position across the drugs and alcohol testing industry,” said Premier CEO Matt Michalik. “NTS adds meaningful client depth to our Government and Behavioral Health businesses, complementary point of care testing solutions with cross sell potential, and a fantastic team to our growing organization. We are thrilled for this partnership.”
Premier Biotech has completed four acquisitions since partnering with ACP in November of 2022. The Company will continue to pursue additional acquisitions and collaboration opportunities to further accelerate its growth. ACP Managing Partner Rob Langley, Operating Partner Ervin Cash, Principal Matt Bowen and Senior Associate Sarah Mahosky worked alongside Premier Management on the transaction.
Disclosures: This press release is not an offer to sell securities or interests in any fund managed by ACP.